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ABSTRACT 
Background: The clinical research in past decade has reported that most 
second-generation antipsychotics (SGAs) can cause serious metabolic 
derangement, which substantially increases the risk for type II diabetes 
mellitus. Several retrospective studies have shown increased in serum 
triglyceride in patients treated with Clozapine. SGAs induced metabolic 
syndrome is characterized by weight gain, hyperglycaemia, hypertension, 
hyperlipidaemia, glucose intolerance and insulin resistance. Metformin is 
currently used to treat metabolic syndrome and type II diabetes mellitus. It is 
therefore important to determine whether Metformin is efficacious in treating 
Clozapine-induced metabolic derangement like dyslipidaemia. Objectives: 
To evaluate the effect of Metformin in minimizing Clozapine induced 
metabolic derangement like dyslipidaemia. Methodology: Wistar rats 
weighing 180-240g either sex were divided into 3 groups of 6 rats each. 
Group 1 served as control, Group 2 Treated with Clozapine 25mg/kg body 
weight and Group 3 Treated with Clozapine 25mg + Metformin 100mg/kg 
body weight for 28 days P.O. Group 2 and group 3 were treated for 28 days. 
Biochemical investigations: Retro-orbital blood was collected for Lipid 
profile. Result: Lipid profile of group 2 rats treated with Clozapine showed 
dyslipidaemia (TG 103.3±1.7mg/dl, Tc 113.7±1.6mg/dl). Whereas group 3 
rats treated with Clozapine 25mg + Metformin showed normal lipid levels 
(TG 94.7±1.7mg/dl, TC 102.8±0.8 mg/dl) comparable to group 1(TG 
93.0±2.6mg/dl, TC 103.7±1.5mg/dl). Conclusion: This study exploring the 
use of Metformin to prevent metabolic derangement like dyslipidaemias in 
patients of schizophrenia treated with Clozapine. 
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INTRODUCTION  
In recent years Second generation antipsychotics (SGAs) 
are effective pharmacotherapeutic agents for various 
neuropsychiatric diseases, especially Schizophrenia, but 
also for bipolar disorder, autism, as a add on therapy in 
many major depressive disorders and are used by millions 
of patients in the world [1]. The major advantage of these 
drugs is that they are less likely to cause neurologic side 
effects. The neurologic side effects of first-generation 
antipsychotics (FGAs) are due to potent dopamine D2 
receptor blockade and are important limiting factors for 
long term use of these agents [2]. The second-generation 
antipsychotics (SGAs) are currently more prescribed due 
to lack of these neurological side effects. SGAs act both 
5HT2 and are weak D2 blocker. In addition, they have 
alpha adrenergic blocking, anticholinergic and H1 
antihistaminic activity. However, the clinical research in 
past decade has reported that most SGAs can cause 
serious metabolic adverse effects like dyslipidaemia, 
resulting in a metabolic syndrome that substantially 
increases the risk for cardio-metabolic disorders, such as 
type II diabetes mellitus and cardiovascular diseases [3]. 
Several studies have reported that there is increased loss 
of life in patients with Schizophrenia. Besides, they have 
higher risks for cerebrovascular illnesses, respiratory 
disorders and mortality from suicide. However, the most 
common reason for death suggested to be cardiovascular 
disorders [4]. With widespread use of these drugs, the 
metabolic adverse effects of antipsychotics are a major 
public health problem and there is a great need for a better 
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understanding for their management. Consistent with the 
literature on type II diabetes mellitus, some success has 
been obtained through lifestyle changes, including 
exercise and dietary modifications [5]. However, these 
changes may be more challenging in the psychiatric 
population [6], therefore the mainstay of treatment 
remains the use of antidiabetic drug like Metformin to 
minimise or to ameliorate metabolic derangement like 
dyslipidaemia. Metformin is being currently used to treat 
metabolic syndrome and type II diabetes mellitus. 
Metformin acts through diverse pharmacological 
mechanisms. Metformin has been demonstrated to reduce 
the incidence of type 2 diabetes mellitus by 31% 
compared to control subjects who received placebo [7]. 
The present study proposes that reduced progression from 
pre-diabetes to diabetes should be a treatment goal for 
patients with Schizophrenia treated with SGAs. Regular 
use of Metformin would be expected to lower the 
progression rate to a considerable extent. It is therefore 
important to determine whether Metformin is efficacious 
in treating SGAs induced metabolic derangement like 
dyslipidaemia. Therefore, the present study is undertaken 
to evaluate the effects of Metformin on metabolic 
derangement like dyslipidaemia caused by Clozapine, a 
SGA drug in a rat model [8]. 
MATERIALS & METHODS 
Study design: An Experimental animal-based study. 
Ethics approval: The study was reviewed and approved 
by the Institutional Animal Ethics Committee (IAEC)vide 
letter reference number; 665/15, dated 07.12.2015. Study 
was carried out as per guidelines of Committee for the 
Purpose of Control and Supervision of Experimentation 
on Animals (CPCSEA). 
Locus of study: BLDEU’s Shri B.M. Patil Medical 
College Hospital &Research Centre, Vijayapur. 
Sample size: 18 Wistar rats 
Sex: Either 
Drugs used: Clozapine: It was procured from Rajesh 
Chemicals co. Mumbai. The dose used was 25mg / kg/ 
day orally. It was dissolved in dilute acetic acid. 
Metformin: It was obtained from Rajesh Chemicals co. 
Mumbai. The dose used was 100mg / kg/ day orally. It 
was dissolved in distilled water. 
Methodology: Wistar rats weighing 180-240g either sex 
bred from a stock obtained from the Central Animal 
House, BLDEU’s Shri BM Patil Medical College 
Hospital & Research Centre, Vijayapur, were used in the 
study. Animals were housed in separate room 3 each in 
polypropylene cages for one week acclimatization before 
the start of the study. The cages were lined with paddy 
husk which was replaced every day and animals were kept 
under standard condition of illumination with a 12 - h 
light-dark cycle at room temperature of 25 ± 1° C and 45-
70% relative humidity. The animals were fed with 
commercial pellet rat chow (manufactured by VRK 
Nutritional solutions, Sangli, Maharashtra) and water ad 
libitum. 
Dose calculation: Rat dose per day is calculated using 
average human dose/day and converted into rat dose using 
following formula: Rat dose/200g = human dose x 0.18. 
Grouping of animals, dose of drug and route of 
administration: 
Animals will be divided into 3 groups of six rats each, 
each group having equal number of male and female rats. 
Group 1: Control (n=6) was given distilled water p.o 
    
Group 2: Received Clozapine (n=6)25mg/kg p.o[9] 
   
Group 3: Received Clozapine25mg/kg + Metformin 
100mg/kg p.o[10]  
All animals had access to food and water ad libitum. 
Dyslipidaemia: Group 2 rats treated with Clozapine for 
28days to produce dyslipidaemia. Whereas group 3 rats 
treated with Clozapine 25mg + Metformin 100mg/kg per 
P.O. for 28days. 
Sample collection: Retro-orbital blood was collected for 
Lipid profile. 
Parameters studied: Triglycerides, Total Cholestrol, 
HDL, LDL, VLDL by auto analyser method  
Statistical analysis: All the values have been expressed 
as the mean ± SEM and analysed by one-way analysis of 
variance (ANOVA) in order to test differences between 
groups. The level of statistical significance has been set at 
p<0.05. 
RESULTS  
Table 1 and Figure 1 shows that Group 2 (Clozapine 
treated rats) showed statistically significant increase in 
serum levels of Triglycerides, Total cholesterol, LDL and 
VLDL levels compared to those in normal control group 
over study period.  
Administration of Clozapine along with Metformin in 
Group 3 (Clozapine + Metformin treated rats) there was 
no such statistically significant increase and was 
comparable to those rats in untreated control group. 
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DISCUSSION 
Major psychosis, Schizophrenia is characterised by its 
chronicity, disordered behavioral function and disturbed 
emotions and thinking. Availability of effective 
antipsychotic drugs has considerably improved the 
outcome. Older or first-generation antipsychotic drugs 
have been used for years. But undesirable effects like 
disorders of movements have been major limiting factor.  
 
 
This resulted in development of newer more effective and 
safe drugs like Clozapine. However, they are also not 
completely free from adverse effects like metabolic 
derangement on long term use. This metabolic 
derangement can be reversed by simultaneous 
administration of drug like Metformin. 
Lipid profile  Days 
Control Clozapine  
Clozapine + 
Metformin ANOVA 
 p value 
Mean±SEM Mean±SEM Mean ±SEM 
Triglyceride 
(mg/dl) 
0 day 91.5±2.6 92.8±1.9 92.0±1.9 0.906 
28 day 93.0±2.6 103.3±1.7 94.7±1.7 0.006* 
Total 
cholesterol 
(mg/dl) 
0 day 101.0±1.4 101.5±0.6 101.7±0.6 0.878 
28 day 103.7±1.5 113.7±1.6 102.8±0.8 <0.001* 
HDL 
(mg/dl) 
0 day 29.8±0.7 29.3±0.3 28.8±0.5 0.427 
28 day 31.7±1.1 31.0±0.4 30.3±0.6 0.444 
LDL 
(mg/dl) 
0 day 52.9±1.7 53.6±0.6 54.4±1.0 0.648 
28 day 53.4±1.8 62.0±1.7 53.6±0.6 0.001* 
VLDL 
(mg/dl) 
0 day 18.3±0.5 18.6±0.4 18.4±0.4 0.906 
28 day 18.6±0.5 20.7±0.3 18.9±0.3 0.006* 
Table 1. Change in mean lipid profile among study groups according to time 
 
Note: *means significant at 5% level of significance (p<0.05) 
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The incidence of diabetes mellitus has been shown to be 
increased in patients treated with SGAs in comparison 
with general population [11]. Several retrospective 
studies shown increased in serum triglyceride in patients 
treated SGAs like Clozapine[12].SGAs drugs induced 
metabolic syndrome is characterized by weight gain, 
hyperprolactemia, hyperlipidaemia, hyperglycaemia, 
glucose intolerance, hypertension cardiovascular disease 
and insulin resistance [13]. For the patients who are taking 
Clozapine, the risk of developing type 2 diabetes during 
the first 6 years is greatest. It has been reported that 
among the patients who took Second generation 
antipsychotic like Clozapine more than 50% become 
overweight [14]. Treatment with Clozapine was 
associated with an average weight gain of 9.8lb over 
10weeks which is as high as any other antipsychotics[10]. 
In one of the studies the prevalence of metabolic 
syndrome has been found to be as high as 24.6% [15]. 
Metabolic syndrome is also predictive of both 
cardiovascular diseases and type 2 diabetes mellitus. This 
may lead to early death [14].These metabolic changes are 
seen regardless of age, sex or duration of antipsychotic 
therapy [16-17]. 
In our study there was a statistically significant increase 
in serum levels of TG, TC, LDL and VLDL in Group 2 
compared to group 1. whereas in Group 3(treated with 
Clozapine + Metformin) there was no significant increase 
in TG, TC, LDL and VLDL similar results have been 
reported by Chen C et al (2013), He studied effects of 
adjunctive Metformin on metabolic derangement in non-
diabetic schizophrenic patients treated with Clozapine 
and found that Metformin significantly reversed the 
metabolic derangement particularly due to its effect on 
triglycerides caused by Clozapine. Metformin also 
reduced body weight significantly. However, beneficial 
effect of Metformin on body weight in Clozapine treated 
patients disappeared on discontinuation of Metformin. 
Metformin is well tolerated by these patients. Thus, it 
supports the strategy for long term Metformin 
supplementation in Clozapine treated patients with 
Schizophrenia and pre-existing metabolic abnormalities 
[18]. 
In our study there was no significant change in serum 
HDL levels and these are also similar with study 
conducted by Ozenoglu et al [19] and he also did not 
report any significant changes in serum levels of HDL.  
CONCLUSION 
The results of this study suggest that Metformin reverses 
the metabolic derangement like dyslipidaemia caused by 
Clozapine in Wistar rats. This raises the possibility that 
Metformin supplementation can be considered to improve 
metabolic derangement like dyslipidaemia in treated with 
Clozapine. Careful monitoring of risk patients may help 
in the prevention of metabolic derangements as well as 
the management of any possible symptoms which they 
occur. 
Limitations: Further studies are required to confirm the 
more beneficial effects of Metformin in the patients who 
are treated with Clozapine. 
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